Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 3/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13012529 | 0.79 | DHFR (0.31) | DHFR | |
| SCHEMBL8869743 | 0.78 | DHFR (0.31) | DHFR | |
| SCHEMBL3132262 | 0.76 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2CDK2 | |
| SCHEMBL13274595 | 0.73 | CDK2 (0.35) | ALDH1A1SMN1; SMN2CDK2 | |
| SCHEMBL10182976 | 0.71 | RORC (0.33) | — | |
| SCHEMBL28243220 | 0.70 | CDK2 (0.39) | CDK2 | |
| SCHEMBL13012534 | 0.67 | DHFR (0.36) | ALDH1A1HTTSMN1; SMN2DHFR | |
| SCHEMBL14477820 | 0.67 | ALDH1A1 (0.33) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL10235024 | 0.67 | CDK2 (0.32) | CDK2 | |
| SCHEMBL25606172 | 0.67 | CDC25A (0.35) | ALDH1A1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | ALDH1A1 1934/4885HTT 4150/4885SMN1; SMN2 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.